The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis
Open accessAbstract
Purpose: Brentuximab vedotin, a monoclonal antibody (cAC10) conjugated to monomethyl auristatin E, targets CD30+ receptors. This phase II open-label trial was conducted to evaluate safety and efficacy in CD30+ cutaneous T-cell lymphomas. Patients and Methods: Forty-eight patients with CD30+ lymphoproliferative disorders or mycosis fungoides (MF) received an infusion of 1.8 mg/kg every 21 days. Results: Forty-eight evaluable patients (22 women and 26 men; median age, 59.5 years) had an overall response rate of 73% (95% CI, 60% to 86%; 35 of 48 patients) and complete response rate of 35% (95% CI, 22% to 49%; 17 of 48 patients). Fifteen (54%; 95% CI, 31% to 59%) of 28 patients with MF responded, independent of CD30 expression. In patients with MF/Sézary syndrome, the overall response rate was 50% (five of 10 patients) in patients with low CD30 expression (< 10%), 58% (seven of 12 patients) in patients with medium expression (10% to 50%), and 50% (three of six patients) in patients with high expression (≥ 50%). Time to response was 12 weeks (range, 3 to 39 weeks), and duration of response was 32 weeks (range, 3 to 93 weeks). All patients with lymphomatoid papulosis (n = 9) and primary cutaneous anaplastic T-cell lymphomas (n = 2) responded; time to response was 3 weeks (range, 3 to 9 weeks), and median duration of response was 26 weeks (range, 6 to 44 weeks). Soluble baseline CD30 levels were lowest in complete responders (P = .036). Grade 1 to 2 peripheral neuropathy was observed in 65% of patients (95% CI, 52% to 79%; 31 of 48 patients), is still ongoing in 55% of patients (95% CI, 41% to 69%; 17 of 31 patients), and resolved in 45% of patients (95% CI, 31% to 59%; 14 of 31 patients), with a median time to resolution of 41.5 weeks. Grade 3 to 4 events were neutropenia (n = 5), nausea (n = 2), chest pain (n = 2), deep vein thrombosis (n = 1), transaminitis (n = 1), and dehydration (n = 1). Dose reductions to 1.2 mg/kg were instituted as a result of grade 2 neuropathy (n = 6), transaminitis (n = 1), and arthralgias and fatigue (n = 2). Conclusion: Brentuximab vedotin is both active and well tolerated in cutaneous T-cell lymphoma and lymphomatoid papulosis, with an overall response rate of 73% and complete response rate of 35%.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
van Dongen, J. J. M., Langerak, A. W., Brüggemann, M., Evans, P. A. S., Hummel, M., Lavender, F. L., Delabesse, E., Davi, F., Schuuring, E., García-Sanz, R., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403202 · Cited by 3,043
Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0410 · Cited by 1,529
Olsen, E., Vonderheid, E., Pimpinelli, N., Willemze, R., Kim, Y., Knobler, R., Zackheim, H., Duvic, M., Estrach, T., Lamberg, S., et al. (2007) · Blood · doi:10.1182/blood-2007-03-055749 · Cited by 1,429
Self-citationBrentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Younes, A., Bartlett, N. L., Leonard, J. P., Kennedy, D. A., Lynch, C. M., Sievers, E. L., & Forero-Torres, A. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002965 · Cited by 1,368
Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M., Connors, J. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0402 · Cited by 997
Thiers, B. H. (2008) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(08)70989-4 · Cited by 974
Francisco, J. A., Cerveny, C. G., Meyer, D. L., Mixan, B. J., Klussman, K., Chace, D. F., Rejniak, S. X., Gordon, K. A., DeBlanc, R., Toki, B. E., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0039 · Cited by 931
Olsen, E. A., Whittaker, S., Kim, Y. H., Duvic, M., Prince, H. M., Lessin, S. R., Wood, G. S., Willemze, R., Demierre, M.-F., Pimpinelli, N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.0630 · Cited by 666
Self-citationKempf, W., Pfaltz, K., Vermeer, M. H., Cozzio, A., Ortiz-Romero, P. L., Bagot, M., Olsen, E., Kim, Y. H., Dummer, R., Pimpinelli, N., et al. (2011) · Blood · doi:10.1182/blood-2011-05-351346 · Cited by 423
Self-citationTransformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis
Diamandidou, E., Colome-Grimmer, M., Fayad, L., Duvic, M., & Kurzrock, R. (1998) · Blood · doi:10.1182/blood.v92.4.1150 · Cited by 334
Self-citationLong-term Outcomes of 1,263 Patients with Mycosis Fungoides and Sézary Syndrome from 1982 to 2009
Talpur, R., Singh, L., Daulat, S., Liu, P., Seyfer, S., Trynosky, T., Wei, W., & Duvic, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0604 · Cited by 289
Self-citationForero‐Torres, A., Leonard, J. P., Younes, A., Rosenblatt, J. D., Brice, P., Bartlett, N. L., Bosly, A., Pinter‐Brown, L., Kennedy, D., Sievers, E. L., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07740.x · Cited by 249
Fanale, M. A., Forero-Torres, A., Rosenblatt, J. D., Advani, R. H., Franklin, A. R., Kennedy, D. A., Han, T. H., Sievers, E. L., & Bartlett, N. L. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1425 · Cited by 213
de Claro, R. A., McGinn, K., Kwitkowski, V., Bullock, J., Khandelwal, A., Habtemariam, B., Ouyang, Y., Saber, H., Lee, K., Koti, K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1803 · Cited by 210
Deng, C., Pan, B.-Q., & O’Connor, O. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0290 · Cited by 148
Josimovic‐Alasevic, O., Dürkop, H., Schwarting, R., Backé, E.-M., Stein, H., & Diamantstein, T. (1989) · European Journal of Immunology · doi:10.1002/eji.1830190125 · Cited by 138
Clonal heterogeneity in mycosis fungoides and its relationship to clinical course
Vega, F., Luthra, R., Medeiros, L. J., Dunmire, V., Lee, S., Duvic, M. A., & Jones, D. M. (2002) · Blood · doi:10.1182/blood.v100.9.3369 · Cited by 137
Self-citationVidulich, K. A., Talpur, R., Bassett, R. L., & Duvic, M. A. (2009) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2009.03771.x · Cited by 115
Self-citationTalpur, R., Jones, D. M., Alencar, A. J., Apisarnthanarax, N., Herne, K. L., Yang, Y., & Duvic, M. A. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700122 · Cited by 112
Self-citationLymphomatoid papulosis and associated lymphomas: a retrospective case series of 84 patients
Kunishige, J. H., McDonald, H. G., Alvarez, G., Johnson, M., Prieto, V. G., & Duvic, M. A. (2009) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.2008.03024.x · Cited by 100
Self-citationSystemic and primary cutaneous anaplastic large cell lymphomas
Kadin, M. E., & Carpenter, C. F. (2003) · Seminars in Hematology · doi:10.1016/s0037-1963(03)00138-0 · Cited by 89
Brentuximab vedotin: An anti-CD30 antibody–drug conjugate
Bradley, A. M., Devine, M., & DeRemer, D. L. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110608 · Cited by 51
Zhang, C., Rangwala, & Duvic, M. A. (2012) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s15564 · Cited by 11
Self-citation
Cited by
Kim, Y. H., Bagot, M., Pinter-Brown, L., Rook, A. H., Porcu, P., Horwitz, S. M., Whittaker, S., Tokura, Y., Vermeer, M., Zinzani, P. L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30379-6 · Cited by 669
Self-citationPrince, H. M., Kim, Y. H., Horwitz, S. M., Dummer, R., Scarisbrick, J., Quaglino, P., Zinzani, P. L., Wolter, P., Sanches, J. A., Ortiz-Romero, P. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31266-7 · Cited by 588
Self-citationAntibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
Staudacher, A. H., & Brown, M. P. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.367 · Cited by 540
Trautinger, F., Eder, J., Assaf, C., Bagot, M., Cozzio, A., Dummer, R., Gniadecki, R., Klemke, C.-D., Ortiz-Romero, P. L., Papadavid, E., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.02.027 · Cited by 452
Clemens, M. W., Jacobsen, E. D., & Horwitz, S. M. (2019) · Aesthetic Surgery Journal · doi:10.1093/asj/sjy331 · Cited by 336
Metadata
- Authors
- Duvic, M., Tetzlaff, M. T., Gangar, P., Clos, A. L., Sui, D., & Talpur, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-11-10
- Volume
- 33
- Issue
- 32
- Pages
- 3759-3765
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2105524669
- Cited by
- 299
- References
- 23
- FWCI
- 36.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.